First human trial launches for targeted radiation therapy against Hard-to-Treat neuroendocrine tumors
Disease control
Ongoing
This early-phase study tests a new radioactive drug, [212Pb] VMT-α-NET, in 24 adults with advanced neuroendocrine tumors that have not responded to other treatments. The main goal is to find a safe dose for future studies, not to treat the disease. Participants receive up to two …
Phase: EARLY_PHASE1 • Sponsor: David Bushnell • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC